We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

BioCision Announces FDA Master File Acceptance for ThawSTAR

BioCision Announces FDA Master File Acceptance for ThawSTAR

BioCision Announces FDA Master File Acceptance for ThawSTAR

BioCision Announces FDA Master File Acceptance for ThawSTAR

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioCision Announces FDA Master File Acceptance for ThawSTAR"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioCision, LLC has announced that the United States Food and Drug Administration (FDA), Center for Devices and Radiological Health, accepted its Device Master File (MAF) submission for the ThawSTAR automated cell thawing system.

“We have seen tremendous global interest for the ThawSTAR technology since launching this product nine months ago and believe it sets a new standard for how cells and cell-based therapies are thawed in-process and in the clinic,” said Rolf O. Ehrhardt, MD, PhD, BioCision Chief Executive Officer.

Utilizing patent-pending STAR™ sensing technology, the ThawSTAR thawing instrument employs multiple detection mechanisms and algorithms to determine vial temperature, phase change initiation and thaw completion, customizing the thaw for each vial containing frozen cellular material.

The system’s intuitive, hands-free operation eliminates the guesswork and subjectivity of determining the thawing end point, setting a new bar in thawing reproducibility and making it a necessary component in processes that rely on standardized procedures.

“Although currently designated for research and investigational use only, we have seen rapid adoption of our ThawSTAR units into cell therapy clinical trials for indications such as diabetes, organ transplantation, heart disease, and others,” continued Ehrhardt. “Having this FDA Master File enables these customers to more easily integrate the product into their workflows and will also provide an added level of quality assurance to our other cGMP customers, such as those in the cord blood and cell banking segments.”

This FDA Master File (reference number MAF2643) encompasses information pertaining to the specifications, materials and quality and manufacturing processes used in producing the ThawSTAR automated cell thawing system.